InflaCare
Financiado
An exosome based therapeutic approach against chronic inflammation
DNA damage triggers the activation of innate immune signaling leading to chronic inflammation and the premature onset of e.g. rheumatoid arthritis, diabetes, metabolic diseases and neurodegenerative disorders in man. Based on our...
DNA damage triggers the activation of innate immune signaling leading to chronic inflammation and the premature onset of e.g. rheumatoid arthritis, diabetes, metabolic diseases and neurodegenerative disorders in man. Based on our ERC consolidator program DeFiNER, we recently discovered that persistent DNA damage triggers the innate immune system stimulating broad inflammatory and antiviral immune countermeasures that lead to chronic inflammation and the premature onset of severe metabolic complications and neurodegeneration in mice. Here, we propose a sophisticated a therapeutic anti-inflammatory strategy aimed at lowering chronic inflammation in preclinical animal models with pronounced metabolic diseases or neurodegeneration. Unlike available anti-inflammatory therapies, the proposed therapeutic approach is non-immunogenic, allows the therapeutic cargo to circulate for extended periods within the body and to cross the blood brain barrier with no biocompatibility complications and minimal to no inherent toxicity issues in mice. This novel strategy provides, therefore, the means towards an innovative medicine that will effectively address real but unmet therapeutic needs for a wide range of devastating diseases associated with chronic inflammation.
ver más
Duración del proyecto: 31 meses
Fecha Inicio: 2019-11-12
Fecha Fin: 2022-06-30
Fecha Fin: 2022-06-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-06-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-POC:
ERC Proof of Concept Grant
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
IDRYMA TECHNOLOGIAS KAI EREVNAS
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
600.99K€ |
Participante